3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Warts
1
Virus Diseases
1
Skin Diseases, Viral
1
Skin Diseases, Infectious
1
Skin Diseases
1
Sexually Transmitted Diseases, Viral
1
Sexually Transmitted Diseases
1
Papillomavirus Infections
1
Condylomata Acuminata
1
Interventions
human papillomavirus vaccine, L1 type 16, 18
30
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
20
Papillomavirus Vaccines
9
Radiotherapy, Intensity-Modulated
4
Cisplatin
4
Blood Specimen Collection
4
fludarabine
3
Vaccines, Synthetic
3
Engerix-B
3
Cyclophosphamide
3
halofantrine
2
fludarabine phosphate
2
aldesleukin
2
Watchful Waiting
2
Vaccines
2
Patient Navigation
2
Paclitaxel
2
Light Coagulation
2
Interleukin-2
2
Imiquimod
2
Human Papillomavirus Recombinant Vaccine nonavalent
2
Hepatitis A Vaccines
2
Fluorouracil
2
Electrocoagulation
2
Cetuximab
2
Carboplatin
2
Albumin-Bound Paclitaxel
2
utomilumab
1
polyphenon E
1
infigratinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Papillomavirus Infections
×
VP-102
×
Clear all
NCT03981822
2024-11-27
CARE-1
Verrica Pharmaceuticals Inc.
Phase 2
Completed
105 enrolled
24 charts